Galec­to ax­es lead can­di­date in lung dis­ease af­ter PhI­Ib miss, stock craters

Galec­to scrapped de­vel­op­ment of its lead can­di­date af­ter the drug missed the pri­ma­ry end­point in a mid-stage lung dis­ease tri­al and said it is “eval­u­at­ing re­source al­lo­ca­tion” to ex­tend its cash run­way in 2025.

The com­pa­ny said Tues­day the GALAC­TIC-1 tri­al had test­ed in­haled galectin-3 pro­tein in­hibitor GB0139 in id­io­path­ic pul­monary fi­bro­sis (IPF), fail­ing to show a re­duc­tion in forced vi­tal ca­pac­i­ty from base­line over the course of 52 weeks. The Phase IIb tri­al en­rolled 173 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER